高级检索
当前位置: 首页 > 详情页

Inflammatory risk factors for hypertriglyceridemia in patients with severe influenza

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

单位: [1]Center for Respiratory Diseases, Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China
出处:
ISSN:

关键词: Hypertriglyceridemia lipid metabolism severe influenza inflammation plasma bronchoalveolar lavage fluid

摘要:
Objective Inflammation and viral infections can induce significant changes in lipid metabolism. Hypertriglyceridemia (HTG) often occurs secondary to obesity, which is an independent risk factor for influenza virus infection. However, the inflammatory risk factors contributing to HTG in patients with severe influenza have yet to be elucidated. Materials and methods Plasma and bronchoalveolar lavage fluid (BALF) samples were collected from 33 patients with severe influenza (n = 26 control patients with normal serum triglyceride levels and n = 7 HTG patients with serum triglycerides >2.3 mM). Levels of 45 putative inflammatory risk factors were quantitated using a commercial enzyme-linked immunosorbent assay kit. Results Plasma levels of interferon (IFN)-gamma, interleukin (IL)-18, IL-1 receptor antagonist (IL-1RA), monocyte chemoattractant protein-1, macrophage inflammatory protein-1 alpha, hepatocyte growth factor, stem cell factor, and vascular endothelial growth factor A were significantly higher in HTG patients compared with control patients. BALF samples from HTG patients contained significantly higher levels of IL-1RA and lower levels of IFN-gamma-inducible protein-10. Conclusion HTG in patients with severe influenza is associated with alterations in several inflammatory risk factors. Our results provide new insights that may enable more effective clinical management of severe influenza combined with HCT.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2019]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 药学
最新[2025]版:
大类 | 4 区 医学
小类 | 4 区 医学:研究与实验 4 区 药学
JCR分区:
出版当年[2018]版:
Q4 PHARMACOLOGY & PHARMACY Q4 MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版:
Q4 MEDICINE, RESEARCH & EXPERIMENTAL Q4 PHARMACOLOGY & PHARMACY

影响因子: 最新[2023版] 最新五年平均[2021-2025] 出版当年[2018版] 出版当年五年平均[2014-2018] 出版前一年[2017版] 出版后一年[2019版]

第一作者:
第一作者单位: [1]Center for Respiratory Diseases, Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China
通讯作者:
通讯机构: [1]Center for Respiratory Diseases, Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, Beijing, China [*1]Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital, No. 2 East Yinghua Street, Chaoyang District, Beijing, P.R. China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:1320 今日访问量:0 总访问量:816 更新日期:2025-04-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)